Under the normalization of centralized mining, there are big moves just after the year of the tiger.
On February 11, the State Council held a regular policy briefing on deepening the reform of centralized procurement of drugs and high-value medical consumables. Chen Jinfu, deputy director of the National Medical Insurance Bureau, said that it would promote the speed-up and expansion of centralized mining. Strive to achieve an average of more than 350 drug varieties and more than 5 high-value medical consumables in each province by the end of 2022 through national organization and provincial alliance procurement, so as to make it a new normal of centralized procurement.
It is worth mentioning that the gathering of the year of the tiger has begun! On February 9, Beijing Pharmaceutical centralized procurement service center and others jointly announced the work plan for joint procurement and use of orthopaedic trauma medical consumables in Beijing Tianjin Hebei "3 + n" alliance, which means that the variety of orthopaedic consumables continues to expand, and the price is expected to be further reduced.
after I'm not a god of medicine
centralized purchase promotes price rationalization
At the press conference held on February 11, Chen Jinfu introduced the achievements of the national organization of centralized drug purchase and responded to the hot issues concerned by the market.
"Imatinib in I am not a god of medicine has increased its use to 35% after intensive collection, so that patients in need of treatment can be fully guaranteed." Introduce Chen Jinfu.
This is only a small section of centralized mining. According to Chen Jinfu, the state has organized the centralized purchase of drugs and purchased 234 kinds of drugs in 6 batches, accounting for about 30% of the purchase amount of chemical and biological drugs in public medical institutions. In 2021, the special procurement of insulin was carried out, and the centralized procurement was expanded from chemical medicine to biological medicine for the first time. The collection of high-value medical consumables focuses on the two areas most concerned by the masses: cardiology and orthopedics. The centralized procurement of cardiac stents has been running smoothly for one year, with a total of 1.69 million successful stents, nearly 1.6 times the annual agreed procurement. Last year, the state organized the centralized collection of artificial joints for more complex orthopaedic consumables, further expanding the coverage of the reform.
At the same time, different forms of provincial and inter provincial alliance centralized procurement have also been carried out. From the perspective of procurement varieties, chemical drugs, Chinese patent drugs and biological drugs are involved, and coronary balloon and ophthalmic intraocular lens have also achieved full provincial coverage.
Chen Jinfu pointed out that centralized mining has promoted the return of prices to a reasonable level, and the masses have benefited significantly. The first six batches of drugs were purchased in a centralized manner, with an average decline of 53%, heart stents by 93%, and artificial hip and knee joints by 82%, which effectively squeezed the space of virtual height. Judging from the cumulative results of the three-year reform, the state has saved more than 260 billion yuan in organizing centralized procurement. The overall drug price level showed a steady downward trend. According to the drug price monitoring data carried out by the medical insurance bureau, the overall drug price level continued to decline in 2019 and 2021, reaching an average annual rate of about 7%.
In addition, the quality of drugs and consumables for clinical use has been steadily improved. Statistically speaking, among the centrally purchased varieties, the share of the original drugs used by the masses and the drugs that have passed the consistency evaluation of quality and efficacy has increased from 50% before centralized purchase to more than 90%. Taking the heart stent as an example, 1 / 3 of the original stent products were stainless steel, but now they are basically eliminated, and the utilization rate of the selected chromium alloy has reached 95%.
dental implants, orthopedics and drug balloons are the focus of this year
On January 10 this year, Premier Li Keqiang presided over the executive meeting of the State Council and decided to carry out the centralized procurement of drugs and high-value medical consumables in a normalized and institutionalized manner, so as to further reduce the medical burden of patients. The meeting pointed out that the centralized purchase of high-value medical consumables should be expanded, and the centralized purchase of implant teeth concerned by the masses should be carried out at the national and provincial levels respectively.
At the meeting, a reporter asked, what is the specific arrangement this year for the varieties of dental implants and other consumables highlighted at the executive meeting of the State Council?
In this regard, Chen Jinfu introduced that dental implant is an important method of restoration and treatment of missing teeth, and the social demand is also great. Medical institutions also provide a lot of services. (dental implants) has been deployed since the beginning of last year. Sichuan has organized an inter provincial alliance to study the procedures for centralized dental implant collection. Now the scheme is basically mature, and the opinions of clinical, enterprises and local governments have been widely listened to. It is prepared to launch such a local alliance reform in the first half of this year. In fact, it is also a layout led by the state, A centralized mining method for dental implant exploration.
At the time of the Winter Olympic Games, the national skiing enthusiasm is high. Recently, a popular saying is: "the end of the snow path is orthopedics". Now coincidentally, orthopedic intensive mining has accelerated. On February 9, Beijing Pharmaceutical centralized procurement service center and others jointly announced the work plan for joint procurement and use of orthopedic trauma medical consumables of Beijing Tianjin Hebei "3 + n" alliance.
At the press conference held on February 11, Chen Jinfu introduced that in the field of orthopaedic consumables, artificial hip and knee joints were recruited last year. At the same time, Henan Alliance launched recruitment in trauma last year, and further extended to spinal consumables this year. In this way, the largest sector of orthopaedic consumables is basically covered by the main body. Spinal consumables are now undergoing thorough research and information standardization, including rules. Recently, we will conduct special research on the joint procurement of high-value medical consumables, widely listen to the opinions of clinical experts and enterprises, and strive to have a preliminary plan in the first half of the year. When the conditions are ripe, the bid opening can be carried out smoothly this year.
In addition, Chen Jinfu also introduced that drug balloon is an important consumables related to cardiology. The drug balloon is not included in the centralized collection, so there is room for price, and this one also has falsely high ingredients. Last year, the collection of drug balloons was carried out in Jiangsu and other places. This year, it will be expanded to the whole country to block the space of virtual height.
centralized purchase promotes the accelerated adjustment of the industry
The acceleration of centralized procurement will undoubtedly have a broad and profound impact on the whole pharmaceutical industry.
For example, in the ongoing intensive collection of orthopaedic materials, Li Yifeng, chief researcher of Guangzhou pebble investment pharmaceutical industry, told reporters: "the centralized collection of orthopaedic materials mainly squeezes the channel links. At the same time, streamlining the charging items and limiting the independent pricing items and charging scale of the hospital have a certain impact on the volume and price."
However, Li Yifeng said that there was a message in the market about centralized procurement that the renewal of centralized procurement is allowed to increase the price, and the enterprise is expected to retain a reasonable profit. For example, during the bidding renewal of the first batch and the third batch of centralized purchase in Jilin Province, the winning price of some products increased by 6% - 126%. In the letter on follow-up work after the expiration of the agreement on centralized drug procurement organized by the state, issued by Shaanxi medical insurance bureau last October, it is also pointed out that the price of the selected products is allowed to rise appropriately when the contract is renewed.
No matter how the centralized purchase changes, its impact on the pharmaceutical industry is irreversible. In view of the continuous expansion of the scope of centralized mining, more enterprises and capital have poured into the innovation track.
Chen Jinfu said that since the centralized procurement, the R & D expenses of some enterprises, especially the head enterprises, have gradually increased. The R & D expenses of some head enterprises have increased from 6% and 10% to 20%, especially in the past two years. What does that mean? On the one hand, leading enterprises can do imitation, on the other hand, more leading enterprises should turn to innovation. Therefore, as long as the demand is here and the investment to improve China's health level is here, there will be a market.
